AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05595109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: which will receive four cycles of AC regimen (doxorubicin and cyclophosphamide; each cycle was given every 21 day) followed by 12 cycles of paclitaxel (each cycle was given in a weekly basis) plus placebo tablets once daily.
Study NCT04834739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beck Depression Inventory
Description: The Beck Depression Inventory (BDI) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression
Study NCT04834739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beck Anxiety Inventory
Description: Beck Anxiety Scale is a 21-item, internationally valid, self-report rating inventory that measures the anxiety level.
Study NCT04834739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 times sit to stand test
Description: The 5XSST scoring is based on the amount of time (to the nearest decimal in seconds) a patient is able to transfer from a seated to a standing position and back to sitting five times. The equipment need in performing 5XSST test includes: Stopwatch and standard height chair with straight back (43-45 cm, 17-18 inches high). Then the instruction is given by asking the test taker to sit on the chair by resting their back. Also, the test taker is instructed to fold their arms across their chest. Then the test taker should be instructed to do sit-to-stand five times, as quickly as possible, at the count of go and without their back or leg resting on the chair between the interval of repetition.
Study NCT04834739 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6 point Likert Scale
Description: Job performance was assessed by asking How do you evaluate your job performance? on 6-point Likert scale.A 6 point likert scale forces choice and gives better data.The 6 point Likert scale offers options for ''Excellent, very good, good, fair, poor and very poor''. 6 point scale anges from 1(very poor) to 5 (excellent).
Study NCT05333224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Family-centered, goal-oriented early physiotherapy approaches will be applied.
Study NCT05333224 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Family-centered, goal-oriented early physiotherapy approaches will be applied.
Study NCT05002686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200 mg Q3W on Day 1 by IV infusion
Study NCT05002686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Paclitaxel
Description: 200 mg/m\^2 Q3W on Day 1 by IV infusion
Study NCT05002686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 orally according to Body Surface Area (BSA) BID Q3W on Days 1-14
Study NCT05002686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 Q3W on Day 1 by IV infusion
Study NCT05002686 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy for gastric lesions and high-risk areas of retroperitoneal lymph node before sugery, 45Gy\*25.
Study NCT05002686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical gastric cancer surgery
Description: Radical gastric cancer surgery with D2 lymph node dissection
Study NCT04998422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HG381
Description: HG381 is available as white to off-white cake or powder for solution for injection at a unit dose strength of 5 mg per vial. HG381 will be administered as IV injection.
Study NCT05282979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel 2
Description: Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide dermal remodeling and collagen restructuring that promote wrinkles appearance improvement.
Study NCT05487365 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comunicare Solutions Smartphone Application
Description: The Comunicare patient support solution is specifically designed for digital support of HF. It consists of an application for patients and a dashboard for the caregivers. The application is a class 1 certified medical device. It includes different modules for patient education, medication adherence, symptoms tracking, electronic patient-reported outcome (ePRO), appointments, and video consultation. Caregiver dashboard application: this web-based application enables caregivers to administrate the care flow and review all patient-reported data and the alarm generated by the system. Security and Privacy: the application complies with strict security and privacy-related regulations. All data storages are encrypted on the patients' smartphone and a server located in an ISO-certified data center located in Belgium, and all information exchanges are highly secured. A GDPR-compliant privacy notice defines how patient personal data is processed and how data protection principles are applied.
Study NCT05487365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Completing a quality of life (QOL)-questionnaire
Description: Patients refusing to use Comunicare app will also be asked to complete a quality of life (QOL)-questionnaire at 0, 6 and 12 months which will be answered online.
Study NCT05466175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olverembatinib
Description: Given PO
Study NCT05466175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given Intravenous
Study NCT05466175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given Intravenous
Study NCT05114759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009
Description: In dose Escalation:~SHR-A2009 will be administered intravenously. Six dose levels are preset.~In dose Expansion:~2 to 3 dose cohorts will be selected for dose expansion stage.~In indication Expansion:~Indications will be selected to evaluate preliminary efficacy.
Study NCT05563818 — intervention group
Intervention type: OTHER
Intervention: WinterLight Mobile Phone Speech Analysis
Description: N/A- observational study
Study NCT05194449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Talk® App
Description: Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.
Study NCT05194449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo App
Description: Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
Study NCT06731556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol
Description: Paracetamol was administered intravenously at a dose of 20 mg/kg/day, twice daily.
Study NCT06731556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Paracetamol
Description: Paracetamol at a concentration of 1.25 mg/mL was administered intranasally.
Study NCT06731556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Diclofenac Sodium
Description: Diclofenac sodium at a concentration of 0.0625 mg/mL was administered intranasally.
Study NCT06731556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ibuprofen
Description: Ibuprofen at a concentration of 0.375 mg/mL was administered intranasally.
Study NCT06759311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin
Study NCT06759311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brix 3000
Description: Brix 3000 gel will be applied to the caries lesion using a spoon excavator\*\* leaving gel according to the manufacturer's instructions. After 2 minutes, the gel will turn from translucent green colour to cloudy after the gel removal.
Study NCT06759311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carie Move
Description: Carie-Move gel will be applied to the caries lesion according to the manufacturer's instructions at second visit in the same child. After 30 second the gel will be removed.
Study NCT06759311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Bur
Description: Removal of carious dentin will be carried out employing smart bur II mounted on a low-speed handpiece without water spray. Caries removal will be proceeded until the smart bur II becomes dull after repeated contact with healthy dentin (21) (figure 3)
Study NCT05557955 — intervention group
Intervention type: OTHER
Intervention: Breathing test
Description: Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
Study NCT06760091 — intervention group
Intervention type: OTHER
Intervention: baseline data collection and follow-up
Description: At the time of enrollment, baseline characteristics will be collected, and each subject will be followed up for 2 years through face-to-face, telephone, or online visits. During the follow-up period, the clinical prognosis will be recorded.
Study NCT06759233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic cryoballoon ablation treatment(ECAT)+PD-1
Description: ECAT: A cryoballoon with catheter is inserted along the endoscopic forceps channel, the balloon is placed on the surface of the tumor, and the balloon is dilated so that it fits snugly over the lesion. The freezing cycle is initiated and continued for 2-3 minutes, and then the balloon is rewarmed and frozen again for 2-3 minutes; the freeze-rewarm cycle is repeated twice.~PD-1:The first PD-1 monoclonal antibody treatment in this study was given within 3 days before and after ECAT treatment, and subsequent treatment was given every three weeks according to the instructions.
Study NCT06758674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Prepared in clear language and supported with visuals in line with guidelines and studies (Kottner et al. 2019, Orhan 2017, APUPA 2011, EPUAP and NPUAP 2009, EPUAP 2019, Arıkan and vanGiersbergen 2019, Arslantaş et al. 2018) training will be given to prevent pressure ulcers. Training content will be sent to expert opinion for content validity. In the content of the training, the definition of pressure ulcers, how they develop, high-risk areas for wound formation, identification of risks, evaluation of the skin, skin care, lying positions and position changes, supporting bone protrusions with pillows, lying on a support surface, nutritional status and content, fluid intake will be discussed.
Study NCT06760117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: Irinotecan will start at a dose of 50mg/m² and escalate to explore the maximum tolerated dose.
Study NCT06760117 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan (CPT-11)
Description: Irinotecan will start at a dose of 50mg/m² and escalate to explore the maximum tolerated dose.
Study NCT06760117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: TMZ：100mg/m2/d，d1-5
Study NCT06760117 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide (TMZ)
Description: TMZ：100mg/m2/d，d1-5
Study NCT06760117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: VCR: 1.5mg/m2/d(≯2mg), d1
Study NCT06760117 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: VCR: 1.5mg/m2/d(≯2mg), d1
Study NCT06759857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND9041
Description: FHND9041 is a novel therapeutic agent targeting EGFR mutations. Participants will take an 80 mg oral dose once daily until disease progression, intolerable toxicity, or meeting other study-defined discontinuation criteria.
Study NCT06759857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib
Description: Afatinib is an approved, second-generation, irreversible EGFR tyrosine kinase inhibitor used as a standard first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, such as L858R and Exon 19 deletions. Participants in this arm will take a 40 mg oral dose once daily. Afatinib serves as the active comparator in this study to evaluate the efficacy and safety of FHND9041.
Study NCT06758726 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mitoxantrone Hydrochloride Liposome combined with BU/Cy
Description: Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day -9, iv Busulfan (3.2mg/kg/d) on day -7\~-5, iv Cyclophosphamide (60 mg/kg/d) on day -3\~-2, iv
Study NCT06760013 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Su Jok Therapy
Description: The researcher, who has a Su-Jok practitioner certificate, applied pressure for 1-2 minutes on the active point on the meridian (the area between the 3rd and 4th fingers pointing to the uterus) that provides energy flow in the palm in 20-minute periods, with the help of a diagnostic probe (diagnostic stick). The point will be determined. Once this point is detected, a massage will be performed on the point. The massage will be applied with a 10-minute rest period between each two periods.
Study NCT06758713 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies.
Study NCT06193005 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT04783246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Fitness
Description: The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.
Study NCT04783246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Fitness
Description: The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.
Study NCT04783246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.
Study NCT04783246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.
Study NCT02734719 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonestim
Description: Bonestim is the multipad electrical stimulation device.
Study NCT05279989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seated Tai Chi Qigong
Description: Participants will receive seated Tai Chi Qigong videos.
Study NCT05279989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Information Videos
Description: Participants will receive videos of health information.
Study NCT04767633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing
Description: The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
Study NCT03394976 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study NCT06323902 — intervention group
Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation
Description: In the operating room through pars plana vitrectomy after having completed the complete air exchange, with the help of a Backwash Charles cannula, the PRGF membrane is placed in the macular hole and C3F8 gas is left in the posterior chamber, the first hour in the recumbent position. supine and subsequently face down during the first postoperative week.
Study NCT05732701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm-guided DAPT duration
Description: PRECISE-DAPT score ≥25~* Chronic Coronary Syndromes (CCS): Aspirin + clopidogrel for 1 month, followed by clopidogrel monotherapy~* Acute Coronary Syndromes (ACS): Aspirin + ticagrelor for 1 month, followed by ticagrelor monotherapy~PRECISE-DAPT score \<25:~* Non-complex CCS: Aspirin + clopidogrel for 6 months, followed by clopidogrel monotherapy~* Non-complex ACS: Aspirin + potent P2Y12 inhibitor for 6 months, followed by potent P2Y12 inhibitor monotherapy~* Complex CCS or ACS: Aspirin + P2Y12 inhibitor for 12 months, followed by P2Y12 inhibitor monotherapy (potent P2Y12 inhibitor mandatory for ACS)
Study NCT05732701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care DAPT duration
Description: DAPT strategy at the operators´ discretion in accordance with applicable guidelines
Study NCT06225427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT06225427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06225427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06225427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study NCT06760403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypochlorous acid
Description: Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.
Study NCT06760403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous acid
Description: Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.
Study NCT06760403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypochlorous acid
Description: Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.
Study NCT06760377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement Group
Description: Subjects belonging to the experimental group will be provided with the PermeaIntest supplement, which they will take for 60 days, 1 sachet in the morning and 1 sachet in the evening in half a glass of water. Subjects will have a stool sample collected before and after ingestion of the dietary supplement.
Study NCT06759896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protraction facemask
Description: Patients assigned to intervention 1 will utilize the Petit protraction facemask, in conjunction with a rapid maxillary expansion (RME). This facemask consists of a forehead pad and chin pad linked by a sturdy steel support rod.
Study NCT06759896 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper partial fixed appliance
Description: Upper partial fixed appliance / 2 by 4 appliance will be used in this study by using bracket set (119-142 Unitek™ Gemini Bracket MBT™ U/L 5x5 0T-Cuspid 3Hk) with molar bands (3M™ Victory Series™ First Molar Bands) or buccal tubes (3M™ Victory Series™ Superior Fit Buccal Tubes) and upper nickel titanium archwires (3M™ Unitek™ Nitinol Heat-activated Archwire) and upper stainless steel archwires (3M™ Unitek™ Permachrome Standard Archwire) .
Study NCT06347432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power wheelchair skills training using the IndieTrainer system
Description: The IndieTrainer system will be used to provide the power wheelchair (PWC) skills training sessions. The IndieTrainer is comprised of a mobility device and an array of video-based gamified training modules designed to facilitate PWC training. The IndieTrainer mobility device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. Principles outlined in the Assessment of Learning Powered mobility use (ALP) Facilitating Strategies for each ALP Assessment phase will guide the intervention sessions.